T1	Participants 137 156	overactive bladder.
T2	Participants 253 292	patients with overactive bladder (OAB).
T3	Participants 392 550	patients with continuous OAB symptoms for ≥ 3 months, daily mean voiding frequency (DMVF) ≥ 8, and daily mean urgency or urgency incontinence frequency
